medigraphic.com

2013, Number 2

<< Back Next >>

Rev Cuba Endoc 2013; 24 (2)

Metabolic syndrome and cardiovascular disease in type 2 diabetes mellitus patients

Valdés RE, Bencosme RN

Language: Spanish
References: 35
Page: 125-135
PDF size: 75.00 Kb.


ABSTRACT

Objective: to ascertain the prevalence of the metabolic syndrome and its relationship with the cardiovascular disease observed in type 2 diabetes mellitus patients.
Methods: a cross-sectional and descriptive study of 1 005 diabetes mellitus type 2 patients admitted to the Center for the Care of Diabetics in Bayamo, Granma province was conducted from October 2008 to July 2011. For the definition of this syndrome, the study used the diagnosing criteria of the World Health Organization, of the Third Report of the National Cholesterol Education Program and of the International Diabetes Federation. The clinical histories provided the demographic, clinical and metabolic data under study.
Results: seven hundred eighty two cases (77.8 %) presented with metabolic syndrome according to the criteria of the International Diabetes Federation; 669 (66.6 %) had it in accordance with the Third Report of the National Cholesterol Education Program and 623 (61.9 %) were also affected according to the World Health Organization. The existence of metabolic syndrome increased the risk of developing ischemic cardiopathy regardless of the diagnostic criteria (p‹ 0.05). None of the risk factors included in the metabolic syndrome was significantly associated to the occurrence of cardiovascular disease when this syndrome was non-existent.
Conclusions: the prevalence of the metabolic syndrome was high in the studied sample. Its presence increased the risk of ischemic cardiopathy, regardless of the diagnostic criteria that are used.


REFERENCES

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.

  2. Grundy SM, Cleeman JI, Daniels SR, Donato KD, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.

  3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.

  4. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-1.

  5. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364-76.

  6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.

  7. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007;99:6B-14B.

  8. Guize L, Pannier B, Thomas F, Bean K, Jégo B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577-83.

  9. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-72.

  10. World Health Organization (WHO). Definition and classification of diabetes mellitus and complications. Report of WHO consultation. Part 1: Diagnosis and classification of Diabetes mellitus. World Health Organization. Department of Noncommunicable Desease Surveillance. Génova: WHO; 1999.

  11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-72.

  12. World Health Organization (WHO). Expert Committee Phycal Status. The use and interpretation of anthropometry. Geneva. WHO Technical Report. 1995; serie no. 854.

  13. Schettler G, Nüssel E. Cholesterol CHOP-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  14. Schettler G, Nüssel E. Triglycerides liquicolor GPO-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  15. Lópes-Virella M, Stone MF, Ellis S. Cholesterol determinations in HDL separated by three different methods. Clin Chem. 1977;23:882-5.

  16. Escobar F. Pie diabético y factores de riesgo. Av Diabetol. 1995;5:71-6.

  17. Ito H, Harano Y, Suzuky M, Hattori y, Takeuchi M, Inada H, et al. Risk factor analyses for macrovascular complication in nonobese NIDDM patients multiclinial study for diabetic macroangiopathy. Diabetes. 1996;45 (Suppl 3):519-23.

  18. Agramonte Martínez M, Barnés Domínguez JA, Pinto Correa MA. Prevalencia del síndrome metabólico en pacientes diabéticos tipo 2. Rev Cubana Med [serie en Internet]. 2009 Mar [citado 7 de septiembre de 2012];48(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75232009000100002&lng=es&nrm=iso&tlng=es

  19. Muñoz Batista MJ, Peña Borrego M, Hernández Gárciga FF, Pérez Lemus JF, Soler Tejera I, Just Matos CC. Síndrome metabólico en pacientes diabéticos tipo 2 pertenecientes al área de salud Guanabo. Rev Cubana Med Gen Integr [serie en Internet]. 2010 Jun [citado 7 de septiembre de 2012];26(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 21252010000200008&lng=es&nrm=iso&tlng=es

  20. Bustillo Solano E, Pérez Francisco Y, Brito García A, González Iglesia A, Castañeda Montano D, Santos González M, et al. Síndrome metabólico, un problema de salud no diagnosticado. Rev Cubana Endocrinol [serie en Internet]. 2011 Dic [citado 8 de septiembre de 2012];22(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532011000300001&lng=es&nrm=iso&tlng=es

  21. Rodríguez Bernardino A, García Polavieja P, Reviriego Fernández J, Serrano Ríos M. Prevalencia del síndrome metabólico y grado de concordancia en su diagnóstico en pacientes con diabetes mellitus tipo 2 en España. Endocrinol Nutr. 2010;57:60-70.

  22. Lombo B, Satizábal C, Villalobos C, Tique C, Kattah W. Prevalencia del síndrome metabólico en pacientes diabéticos. Acta Med Colomb. 2007 Mar;32(1):9-15.

  23. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007;99:6B-14B.

  24. Valdés Ramos E, Bencosme Rodríguez N. Las complicaciones macrovasculares y su relación con algunas variables clínicas y bioquímicas en diabéticos tipo 2. Rev Cubana Endocrinol [serie en Internet]. 2010 Dic [citado 14 de enero de 2012];21(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532010000300001&lng=es&nrm=iso&tlng=es

  25. Grima A, León M, Ordóñez B. El síndrome metabólico como factor de riesgo cardiovascular. Rev Esp Card. 2006;5:16-20.

  26. Olijhoek JK, Van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2004;25:342-8.

  27. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-14.

  28. Chol KM, Kim SM, Kim YE, Chol DS, Balk SH, Lee J, International Diabetes Federation. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. Metabolism. 2007;56:552-8.

  29. Muñoz Roldán I, Martín Puig M, Agudo Villa M, Recarte García C, Millán J. Riesgo cardiovascular en pacientes diabéticos tipo 2 con o sin síndrome metabólico asociado. Clin Invest Arterioscl. 2011;23(3):112-8.

  30. Calbo MJM, Terrancle I, Solera Santos J. Síndrome metabólico y enfermedad arterial periférica. Rev Clin Esp. 2007;207:101-2.

  31. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.

  32. Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-6.

  33. Kahn R. ¿Puede considerarse el síndrome metabólico un verdadero síndrome? Circulation. 2007;115(13):1806-11.

  34. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32(suppl 1):S13-61.

  35. Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29:1316-26.




2020     |     www.medigraphic.com